Next stop for the CRISPR revolution: RNA-guided epigenetic regulators

FEBS Journal

Volumn , Issue , 2016, Pages 3181-3193

  Vora, Suhani ^a,b,c   Tuttle, Marcelle ^a   Cheng, Jenny ^a   Church, George ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

activation; clustered regularly interspaced short palindromic repeats; CRISPR associated protein 9; epigenetic; repression; transcription

Indexed keywords

CRISPR ASSOCIATED PROTEIN; DNA; NUCLEASE; RNA; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER PROTEIN;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA MODIFICATION; ENZYME ACTIVITY; EPIGENETICS; GENE SEQUENCE; GENE TARGETING; GENETIC REGULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TECHNOLOGY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 84986199979     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13768     Document Type: Review

References (74)

1. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD & Blancafort P (2012) Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 7, 350–360.
2. Snowden AW, Gregory PD, Case CC & Pabo CO (2002) Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol 12, 2159–2166.
3. Mendenhall EM, Williamson KE, Reyon D, Zou JY, Ram O, Joung JK & Bernstein BE (2013) Locus-specific editing of histone modifications at endogenous enhancers. Nat Biotechnol 31, 1133–1136.
4. Konermann S, Brigham MD, Trevino A, Hsu PD, Heidenreich M, Cong L, Platt RJ, Scott DA, Church GM & Zhang F (2013) Optical control of mammalian endogenous transcription and epigenetic states. Nature 500, 472–476.
5. Maeder ML, Linder SJ, Reyon D, Angstman JF, Fu Y, Sander JD & Joung JK (2013) Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods 10, 243–245.
6. Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ & Gersbach CA (2013) Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods 10, 239–242.
7. Bernstein DL, Le Lay JE, Ruano EG & Kaestner KH (2015) TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. J Clin Invest 125, 1998–2006.
8. Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, Ho QH, Sander JD, Reyon D, Bernstein BE et al. (2013) Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol 31, 1137–1142.
9. Dhanasekaran M, Negi S & Sugiura Y (2006) Designer zinc finger proteins: tools for creating artificial DNA-binding functional proteins. Acc Chem Res 39, 45–52.
10. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, Jiang T, Foley JE, Winfrey RJ, Townsend JA et al. (2008) Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31, 294–301.
11. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD & Joung JK (2012) FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30, 460–465.
12. Bolotin A, Quinquis B, Sorokin A & Ehrlich SD (2005) Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551–2561.
13. Mojica FJM, Díez-Villaseñor C, García-Martínez J & Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60, 174–182.
14. Pourcel C, Salvignol G & Vergnaud G (2005) CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653–663.
15. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA & Horvath P (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712.
16. Tang T-H, Bachellerie J-P, Rozhdestvensky T, Bortolin M-L, Huber H, Drungowski M, Elge T, Brosius J & Hüttenhofer A (2002) Identification of 86 candidates for small non-messenger RNAs from the archaeon Archaeoglobus fulgidus. Proc Natl Acad Sci USA 99, 7536–7541.
17. Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, Dickman MJ, Makarova KS, Koonin EV & van der Oost J (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960–964.
18. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJJ, Charpentier E, Haft DH et al. (2015) An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 13, 722–736.
19. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA & Charpentier E (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821.
20. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823.
21. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE & Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339, 823–826.
22. Jinek M, East A, Cheng A, Lin S, Ma E & Doudna J (2013) RNA-programmed genome editing in human cells. Elife 2, e00471.
23. Deveau H, Barrangou R, Garneau JE, Labonté J, Fremaux C, Boyaval P, Romero DA, Horvath P & Moineau S (2008) Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol 190, 1390–1400.
24. Mojica FJM, Díez-Villaseñor C, García-Martínez J & Almendros C (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733–740.
25. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA & Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281–2308.
26. Kosuri S & Church GM (2014) Large-scale de novo DNA synthesis: technologies and applications. Nat Methods 11, 499–507.
27. CustomArray, Inc. – maker of custom microarrays, oligo pools and instrumentation.
28. Sander JD & Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32, 347–355.
29. Weeks DP, Spalding MH & Yang B (2015) Use of designer nucleases for targeted gene and genome editing in plants. Plant Biotechnol J 14, 483–495.
30. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L & Church GM (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31, 833–838.
31. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH & Joung JK (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10, 977–979.
32. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW et al. (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10, 973–976.
33. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Weissman JS et al. (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451.
34. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivalila CS, Dadon DB & Jaenisch R (2013) Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 23, 1163–1171.
35. Balboa D, Weltner J, Eurola S, Trokovic R, Wartiovaara K & Otonkoski T (2015) Conditionally stabilized dCas9 activator for controlling gene expression in human cell reprogramming and differentiation. Stem Cell Reports 5, 448–459.
36. Chakraborty S, Ji H, Kabadi AM, Gersbach CA, Christoforou N & Leong KW (2014) A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Reports 3, 940–947.
37. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS & Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635–646.
38. Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Iyer EPR, Lin S, Kiani S, Guzman CD, Wiegand DJ et al. (2015) Highly efficient Cas9-mediated transcriptional programming. Nat Methods 12, 326–328.
39. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC et al. (2014) Genome-Scale CRISPR-mediated control of gene repression and activation. Cell 159, 647–661.
40. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H et al. (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588.
41. Zalatan JG, Lee ME, Almeida R, Gilbert LA, Whitehead EH, La Russa M, Tsai JC, Weissman JS, Dueber JE, Qi LS et al. (2015) Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339–350.
42. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE & Gersbach CA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33, 510–517.
43. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP & Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183.
44. Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE & Gersbach CA (2015) Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods 12, 1143–1149.
45. Kearns NA, Pham H, Tabak B, Genga RM, Silverstein NJ, Garber M & Maehr R (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods 12, 401–403.
46. Kiani S, Chavez A, Tuttle M, Hall RN, Chari R, Ter-Ovanesyan D, Qian J, Pruitt BW, Beal J, Vora S et al. (2015) Cas9 gRNA engineering for genome editing, activation and repression. Nat Methods 12, 1051–1054.
47. Dahlman JE, Abudayyeh OO, Joung J, Gootenberg JS, Zhang F & Konermann S (2015) Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat Biotechnol 33, 1159–1161.
48. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F & Marraffini LA (2013) Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res doi: 10.1093/nar/gkt520.
49. Sternberg SH, LaFrance B, Kaplan M & Doudna JA (2015) Conformational control of DNA target cleavage by CRISPR–Cas9. Nature 527, 110–113.
50. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M et al. (2014) CRISPR-Cas9 Knockin mice for genome editing and cancer modeling. Cell 159, 440–455.
51. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS et al. (2015) In vivo genome editing using staphylococcus aureus Cas9. Nature 520, 186–191.
52. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, Cheng AW, Trevino AE, Konermann S, Chen S et al. (2014) Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 32, 670–676.
53. Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L, Safi A, Crawford GE, Reddy TE & Gersbach CA (2015) Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Res 25, 1158–1169.
54. The difficulty of a fair comparison. Nat Methods 12, 273–273.
55. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O et al. (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31, 827–832.
56. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ & Root DE (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32, 1262–1267.
57. Chari R, Mali P, Moosburner M & Church GM (2015) Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat Methods 12, 823–826.
58. Wong N, Liu W & Wang X (2015) WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system. Genome Biol 16, 218.
59. Zincarelli C, Soltys S, Rengo G & Rabinowitz JE (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16, 1073–1080.
60. Gaudet D, de WJ, Tremblay K, Déry S, van DS, Freidig A, Brisson D & Méthot J (2010) Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 11, 55–60.
61. Mingozzi F & High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12, 341–355.
62. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M & Zhang F (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33, 102–106.
63. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ & Church GM (2013) Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10, 1116–1121.
64. Kearns NA, Genga RMJ, Enuameh MS, Garber M, Wolfe SA & Maehr R (2014) Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development 141, 219–223.
65. Gao X, Tsang JCH, Gaba F, Wu D, Lu L & Liu P (2014) Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res 42, e155–e155.
66. Limsirichai P, Gaj T & Schaffer DV (2016) CRISPR-mediated activation of latent HIV-1 expression. Mol Ther 24, 499–507.
67. Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R, Fagan PR, Putatunda R, Young W-B, Khalili K et al. (2015) CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep 5, 16277.
68. Lin S, Ewen-Campen B, Ni X, Housden BE & Perrimon N (2015) In vivo transcriptional activation using CRISPR-Cas9 in drosophila. Genetics 201, 433–442.
69. Lee JT (2012) Epigenetic regulation by long noncoding RNAs. Science 338, 1435–1439.
70. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG et al. (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22, 1775–1789.
71. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC, Madhavan S, Pan X, Ran FA, Yan WX et al. (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403–407.
72. Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA et al. (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411.
73. Wojtal D, Kemaladewi DU, Malam Z, Abdullah S, Wong TWY, Hyatt E, Baghestani Z, Pereira S, Stavropoulos J, Mouly V et al. (2016) Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited disorders. Am J Hum Genet 98, 90–101.
74. Annex I.Glybera, INN-alipogene tiparvovec. Summary of Product Characteristics.